SecBot SecBot
COURT-RULING ·Filed Aug 31, 2026

AZN

ASTRAZENECA PLC
BEARISH
Impact 3/10
Horizonimmediate Processed2mo ago CourtCourt Ruling · govinfo.gov
Court ruling (district)
Actionable Insight ▼ Bearish

The ruling is a definitive loss but financially trivial for AstraZeneca. No material stock impact expected given the small dollar exposure and consistency with prior court decisions. Monitor for any appeal (unlikely given dismissal with prejudice and weak legal merits). The broader 340B contract pharmacy landscape remains unchanged.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$162.47
T+0 close · Sep 1, 2026 · via day close
Latest settled
−0.62%
T+20 · $161.47 · next T+60 in 8d
Vs SPY
−0.98%
α at T+20
Latest observation
+14.90%
T+52 · FF3 residual α
  1. T+0 · Sep 1 $162.47entry
  2. T+1 · 3mo ago −0.52%α −0.96% · $161.63
  3. T+5 · 2mo ago −3.40%α −3.49% · $156.94
  4. T+20 · 7w ago −0.62%α −0.98% · $161.47
  5. T+53 · todayOpen
  6. T+60 · in 8d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AstraZeneca's lawsuit challenging Colorado's 340B contract pharmacy protection law (S.B. 71) was dismissed with prejudice. The court rejected all constitutional claims (preemption, patent, Contracts Clause, Takings Clause), finding the law does not conflict with federal 340B requirements and that AstraZeneca's voluntary participation in 340B forecloses its takings argument. The ruling is consistent with a nationwide pattern of similar losses for drug manufacturers.

Court Ruling Details

Ruling Date
Aug 31, 2026
Court
United States District Court for the District of Colorado
Court Level
District
Judge
Philip A. Brimmer
Case Type
regulatory
Ruling Type
final judgment
Outcome
LOSS: ruling against this company
Precedent Risk
LOW

Key Facts

  • AstraZeneca's constitutional challenge to Colorado's S.B. 71 (340B contract pharmacy protection) dismissed with prejudice on all claims
  • Court found standing but rejected preemption, patent, Contracts Clause, and Takings Clause arguments
  • AstraZeneca estimated $600,000/month loss from complying with S.B. 71's unlimited contract pharmacy requirement
  • Ruling aligns with multiple other federal courts that have rejected similar manufacturer challenges to state 340B laws
  • No damages awarded, no injunction issued; case closed

Financial Impact

AstraZeneca estimated $600,000/month in additional costs (~$7.2M annually), which is immaterial relative to $251.4B market cap (0.003%)

revenue

Risk Factors

  • No material financial risk identified; the $600k/month estimate is de minimis for a $251B market cap company

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (35 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 court opinion.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-cb9aa174bf-AZN

Track record

77 reports on AZN

Performance horizon

18 of 37 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 28 of 37 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
  2. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.02 −0.82% settles Nov 23
  3. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.02 −0.70% settles Nov 23
  4. Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.02 −0.58% settles Nov 23
  5. Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.02 −1.51% ▼ −1.32% −4.61% vs SPY
  6. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  7. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  8. Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.02 −1.41% ▼ −0.12% +2.59% vs SPY
  9. Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.02 +8.20% ▲ +8.11% +10.10% vs SPY
  10. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.02 +6.63% ▲ +0.51% −0.19% vs SPY
Showing 10 of 77

US Market Status

Market Closed · Opens Wed (11h 35m)

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ Court Ruling · govinfo.gov Report published Sep 1, 2026